Last checked at 4 Mar 2021 15:00
4 March 2021 15:00 GMT
Designation of EU home member state for EU securities regulation purposes
Following the exit of the United Kingdom from the European Union, AstraZeneca PLC (AstraZeneca) announces that it has selected Sweden as its home member state for EU securities regulation purposes pursuant to the Swedish Securities Market Act (Sw. lagen (2007.528) om värdepappersmarknaden).
AstraZeneca will file certain regulatory information with the Swedish Financial Supervisory Authority in accordance with applicable EU and Swedish law. These filings will be in addition to AstraZeneca's continuing disclosure obligations under applicable UK law, including the UK Disclosure Guidance and Transparency Rules. AstraZeneca's status as a UK PLC and the location of its headquarters in the United Kingdom remain unchanged.
AstraZeneca's selection of Sweden as its home member state for EU securities regulation purposes also means that certain continuing notification obligations pursuant to Swedish law will apply to dealings or interests in AstraZeneca securities in addition to the existing obligations under the UK Disclosure Guidance and Transparency Rules. These include notifications as soon as holdings of financial instruments or short positions reach, exceed or go below certain thresholds. AstraZeneca recommends its shareholders to inform themselves about the notification obligations under Swedish law and to consult with their legal advisers in case of any questions.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Additional information
This information is information that AstraZeneca PLC is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact persons set out above, at 15:00 on 4 March 2021.
Adrian KempCompany Secretary
AstraZeneca PLC